Table 1 Demographic and baseline data a
From: Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
N=17 | |
|---|---|
Age (years), Mean (SD) | 31.8 (10.9) |
Sex (female) | 9 (52.9%) |
Brain | |
Cortical Tubers | 14 (82.4%) |
Seizures | 11 (64.7%) |
Cognitive Impairment | 11 (64.7%) |
Astrocytomab | 3 (17.7%) |
Skin | |
Facial angiofibroma | 17 (100.0%) |
Hipomelanotic macules | 15 (88.2%) |
Ungual fibroma | 6 (35.3%) |
Shagreen patch | 9 (52.9%) |
Renal | |
Angiomyolipomas 5 | 1 ( 5.9%) |
10 | 1 ( 5.9%) |
Multiple | 15 (88.2%) |
Vascular embolization | 3 (17.7%) |
Nephrectomy | 3 (17.64%) |